Raydiant Oximetry Oversubscribes Series A $7.5 Million Extension Round
Summary
The companys products have tremendous potential to generate strong returns for our fund while saving and improving the lives of women and children in multiple markets globally, says Annie Th\xe9riault, Managing Partner at CBIV. The first Lumerah participant was enrolled into the study on May 15, 20242.Daisy is a novel surgical device designed to quantify blood loss, treat uterine atony and prevent post-partum hemorrhage (PPH) after a C-section delivery. I have little doubt that Lumerah and Daisy can become the standard of care for all childbirths worldwide.We are honored to partner with funds that recognize the life-saving potential of our groundbreaking devices and share our mission, vision and values, says Raydiant Oximetry founder and CEO Neil P. Ray, MD. The company was founded by Neil P. Ray, MD, a pediatric anesthesiologist, to find a solution to the pervasive problem of identifying fetal distress and potentially avoiding medically unnecessary C-sections, which can have short- and long-term implications for the mother and child. The company has developed two innovative technologies, Lumerah, a low-cost, non-invasive sensor that continuously monitors fetal oxygenation during labor, and Daisy, a novel surgical device designed to quantify blood loss, treat uterine atony and prevent post-partum hemorrhage (PPH) after a C-section delivery.